Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ Cytotoxic T Lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: Implications for L1 dendritic cell-based therapeutic vaccines

Journal of Virology

Volumn 83, Issue 13, 2009, Pages 6779-6789

  Bellone, Stefania ^b   El Sahwi, Karim ^b   Cocco, Emiliano ^b   Casagrande, Francesca ^b   Cargnelutti, Marilisa ^b   Palmieri, Michela ^a   Bignotti, Eliana ^a   Romani, Chiara ^a   Silasi, Dan Arin ^b   Azodi, Masoud ^b   Schwartz, Peter E ^b   Rutherford, Thomas J ^b   Pecorelli, Sergio ^a   Santin, Alessandro D ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; DENDRITIC CELL VACCINE; PROTEIN E6; PROTEIN E7; RECOMBINANT PROTEIN; CANCER VACCINE; CAPSID PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; VIRUS RNA;

ARTICLE; CANCER CELL DESTRUCTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; VIRUS LIKE AGENT; ADULT; AGED; DENDRITIC CELL; FEMALE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE; PAPILLOMAVIRIDAE;

ADULT; AGED; CANCER VACCINES; CAPSID PROTEINS; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 67449094695     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02443-08     Document Type: Article

References (42)

1. Aiba, S., M. Rokugo, and H. Tagami. 1986. Immunohistologic analysis of the phenomenon of spontaneous regression of numerous flat warts. Cancer 58:1246-1251. (Pubitemid 16053136)
2. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252. (Pubitemid 28155090)
3. high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108:2655-2661.
4. Bosch, F. X., A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-265.
5. Coleman, N., H. D. Birley, A. M. Renton, N. F. Hanna, B. K. Ryait, M. Byrne, D. Taylor-Robinson, and M. A. Stanley. 1994. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102:768-774.
6. Cubie, H. A., A. L. Seagar, E. McGoogan, J. Whitehead, A. Brass, M. J. Arends, and M. W. Whitley. 2001. Rapid real-time PCR to distinguish between high risk human papillomavirus types 16 and 18. Mol. Pathol. 54:24-29.
7. de Boer, M. A., E. S. Jordanova, G. G. Kenter, A. A. Peters, W. E. Corver, J. B. Trimbos, and G. J. Fleuren. 2007. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin. Cancer Res. 13:132-138.
8. De Bruijn, M. L., H. L. Greenstone, H. Vermeulen, C. J. Melief, D. R. Lowy, J. T. Schiller, and W. M. Kast. 1998. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250:371-376. (Pubitemid 28489636)
9. De la Rosa, G. P., A. Monroy-García, M. Mora-García, C. G. Peña, J. Hernández-Montes, B. Weiss-Steider, and M. A. Gómez Lim. 2009. An HPV-16 L1-based chimeric human papillomavirus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol. J. 6:2.
10. Demotz, S., H. M. Grey, and A. Sette. 1990. The minimal number of class II MHC-antigen complexes needed for T-cell activation. Science 249:1028-1030. (Pubitemid 20286819)
11. Frattini, M. G., H. B. Lim, and L. A. Laimins. 1996. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc. Natl. Acad. Sci. USA 93:3062-3067.
12. Frazer, I. H., J. T. Cox, E. J. Mayeaux, Jr., E. L. Franco, A. B. Moscicki, J. M. Palefsky, D. G. Ferris, A. S. Ferenczy, and L. Villa. 2006. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr. Infect. Dis. J. 25(Suppl. 2):S65-S81.
13. Harding, C. V., and E. R. Unanue. 1990. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 346:574-576. (Pubitemid 20238811)
14. Harro, C. D., Y. Y. Pang, R. B. Roden, A. Hildesheim, Z. Wang, M. J. Reynolds, T. C. Mast, R. Robinson, B. R. Murphy, R. A. Karron, J. Dillner, J. T. Schiller, and D. R. Lowy. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:284-292.
15. Hildesheim, A., R. Herrero, S. Wacholder, A. C. Rodriguez, D. Solomon, M. C. Bratti, J. T. Schiller, P. Gonzalez, G. Dubin, C. Porras, S. E. Jimenez, and D. R. Lowy. 2007. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743-753. (Pubitemid 47263157)
16. Hopfl, R., K. Heim, N. Christensen, K. Zumbach, U. Wieland, B. Volgger, A. Widschwendter, S. Haimbuchner, E. Muller-Holzner, M. Pawlita, H. Pfister, and P. Fritsch. 2000. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356:1985-1986.
17. Kadish, A. S., G. Y. Ho, R. D. Burk, Y. Wang, S. L. Romney, R. Ledwidge, and R. H. Angeletti. 1997. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst. 89:1285-1293.
18. Kadish, A. S., P. Timmins, Y. Wang, G. Y. Ho, R. D. Burk, J. Ketz, W. He, S. L. Romney, A. Johnson, R. Angeletti, M. Abadi, et al. 2002. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol. Biomarkers Prev. 11:483-488.
19. Monroy-Garcia, A., B. Weiss-Steider, J. Hernandez-Montes, V. F. Ortiz- Navarrete, A. Banuelos-Panuco, A. Acosta-Araujo, A. Diaz-Quinonez, C. M. Lopez-Graniel, G. Herbert, J. Granados, C. de Leo, R. M. Silva-Lopez, and M. L. Mora-Garcia. 2002. Identification of two homologous antigenic peptides derived from L1 HPV-16 and -18 proteins specific for the HLA-B*3901 allele. Arch. Virol. 147:1933-1942.
20. Nakagawa, M., D. P. Stites, S. Farhat, J. R. Sisler, B. Moss, F. Kong, A. B. Moscicki, and J. M. Palefsky. 1997. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J. Infect. Dis. 175:927-931.
21. Osada, T., T. M. Clay, C. Y. Woo, M. A. Morse, and H. K. Lyerly. 2006. Dendritic cell-based immunotherapy. Int. Rev. Immunol. 25:377-413.
22. Pinto, L. A., J. Edwards, P. E. Castle, C. D. Harro, D. R. Lowy, J. T. Schiller, D. Wallace, W. Kopp, J. W. Adelsberger, M. W. Baseler, J. A. Berzofsky, and A. Hildesheim. 2003. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188:327-338.
23. Rogozinski, T. T., S. Jablonska, and M. Jarzabek-Chorzelska. 1988. Role of cell-mediated immunity in spontaneous regression of plane warts. Int. J. Dermatol. 27:322-326.
24. Rudolf, M. P., J. D. Nieland, D. M. DaSilva, M. P. Velders, M. Muller, H. L. Greenstone, J. T. Schiller, and W. M. Kast. 1999. Induction of HPV16 capsid protein-specific human T-cell responses by virus-like particles. Biol. Chem. 380:335-340.
25. Santin, A. D., S. Bellone, M. Gokden, M. J. Cannon, and G. P. Parham. 2002. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N. Engl. J. Med. 346:1752-1753.
26. Santin, A. D., S. Bellone, M. Palmieri, A. Ravaggi, C. Romani, R. Tassi, J. J. Roman, A. Burnett, S. Pecorelli, and M. J. Cannon. 2006. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol. Oncol. 100:469-478.
27. Santin, A. D., S. Bellone, M. Palmieri, A. Zanolini, A. Ravaggi, E. E. Siegel, J. J. Roman, S. Pecorelli, and M. J. Cannon. 2008. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination in stage IB or IIA cervical cancer patients: a phase I escalating dose trial. J. Virol. 82:1968-1979. (Pubitemid 351206942)
28. Santin, A. D., P. L. Hermonat, A. Ravaggi, S. Bellone, C. Cowan, S. Korourian, S. Pecorelli, M. J. Cannon, and G. P. Parham. 2000. Development, characterization, and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7-pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. Eur. J. Gynaecol. Oncol. 21:17-23.
29. + cytotoxic T lymphocytes. J. Virol. 74:4729-4737.
30. + cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin. Cancer Res. 7:804s-810s.
31. + lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J. Virol. 73:5402-5410.
32. Schuler, G., and R. M. Steinman. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1183-1187.
33. Shafti-Keramat, S., A. Handisurya, E. Kriehuber, G. Meneguzzi, K. Slupetzky, and R. Kirnbauer. 2003. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77:13125-13135. (Pubitemid 37494308)
34. Stoler, M. H., C. R. Rhodes, A. Whitbeck, S. M. Wolinsky, L. T. Chow, and T. R. Broker. 1992. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23:117-128.
35. Sykulev, Y., M. Joo, I. Vturina, T. J. Tsomides, and H. N. Eisen. 1996. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T-cell response. Immunity 4:565-571. (Pubitemid 26233310)
36. Valitutti, S., S. Muller, M. Cella, E. Padovan, and A. Lanzavecchia. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148-152.
37. + regulatory T cells specific for human papillomavirus antigens. Proc. Natl. Acad. Sci. USA 104:12087-12092.
38. Villa, L. L., R. L. Costa, C. A. Petta, R. P. Andrade, K. A. Ault, A. R. Giuliano, C. M. Wheeler, L. A. Koutsky, C. Malm, M. Lehtinen, F. E. Skjeldestad, S. E. Olsson, M. Steinwall, D. R. Brown, R. J. Kurman, B. M. Ronnett, M. H. Stoler, A. Ferenczy, D. M. Harper, G. M. Tamms, J. Yu, L. Lupinacci, R. Railkar, F. J. Taddeo, K. U. Jansen, M. T. Esser, H. L. Sings, A. J. Saah, and E. Barr. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278.
39. Wang-Johanning, F., D. W. Lu, Y. Wang, M. R. Johnson, and G. L. Johanning. 2002. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 94:2199-2210. (Pubitemid 34411978)
40. + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14:178-187.
41. Zhang, L. F., J. Zhou, S. Chen, L. L. Cai, Q. Y. Bao, F. Y. Zheng, J. Q. Lu, J. Padmanabha, K. Hengst, K. Malcolm, and I. H. Frazer. 2000. HPV6b virus-like particles are potent immunogens without adjuvant in man. Vaccine 18:1051-1058.
42. Zhou, W., S. K. Tyring, M. Brysk, and T. S. Chan. 1996. Immortalization of differentiated human keratinocytes by human papillomavirus (HPV) 16 DNA. J. Dermatol. Sci. 13:140-152.